Human Milk Oligosaccharides – Part 2 Presented by Lars Bode, PhD Lars Bode, PhD presents and overview of Human Milk Oligo Saccharides, what they are, their metabolism and how HMOs serve as prebiotics. HMOs are the third most abundant component in human milk and their composition follows a basic blueprint. There are more than 150 different HMOs identified. This video presentation includes a very informative Q&A session following the overview.

Human Milk Oligosaccharides – Part 1, Presented by Lars Bode, PhD Lars Bode, PhD presents an overview of human milk oligosaccharides (HMOs), what they are, their metabolism, and how they serve as prebiotics. HMOs are the third most abundant component in human milk, and their composition follows a basic blueprint. There are more than 150 different HMOs identified.  

Lars Bode, PhD: Potential Effects of HMOs on Adult Gut Microbiome Lars Bode, PhD discusses the health benefits of Human Milk Oligosaccharides (HMOs) and how research has shown ways HMOs can effect the adult microbiome. Positive effects are seen specifically in breastfed infants, where it has been identified to raise levels of two prime fucosyllactose (2′FL).

In this Clinical Minute, Nikky Contractor, PhD discusses oligosaccharides. 2’-fucosyllactose, also known as 2'-FL and pronounced “two F L,” is the most abundant human milk oligosaccharide (HMO) in human breast milk. Human milk contains many chemical structures that support the growth of beneficial bacteria in infants. The bacteria that are beneficial to infants are also beneficial in adults and support the growth of beneficial bacteria. 2'FL is also a “decoy receptor” that can bind with pathogenic bacteria and prevent binding…

Prebiotics and Quality Carbohydrates: Enhancing Digestive Health Prebiotics are non-digestible carbohydrates that selectively stimulate the growth and activity of beneficial gut bacteria. Some beneficial gut bacterial can metabolize prebiotics, which gives them a growth advantage. Some prebiotics have more specialized benefits and can play a protective role in gut function. This is especially true for selected oligosaccharides called two prime fucosyllactose, or 2’FL, that are naturally produced and are identical to oligosaccharides originally identified in breast milk, referred to as…

We know that many health conditions have underlying chronic inflammation that can make disease management and treatment more complex. Inflammatory bowel conditions, such as IBD or Crohn’s Disease are closely related to inflammation. In this short video with Dr. Serhan of Harvard Medical School, Metagenics Institute inquires about the opportunities to treat IBD and Crohn’s Disease with SPMs for resolution of inflammation. In animal models, there are encouraging result on three resolvins: D1; Mar1; and E1. Each of these is…

While SPMs offer an exciting opportunity to treat and manage the inflammation often associated with chronic disease, it is crucial to consider the correct amount of SPM for various clinical conditions. In this short video with Dr. Charles Serhan of Harvard Medical School, MHICN inquires about the correct dose of SPM in humans. Dr. Serhan responds that the correct dosing levels have yet to be established fully. Questions that remain include: does gender play a role? Does age play a…

Specialized Pro-Resolving Mediators (SPMs) offer an exciting opportunity to treat and manage the inflammation often associated with chronic disease. The precursors to SPMs are Omega-3 essential fatty acids, EPA and DHA. In this short video with Dr. Charles Serhan of Harvard Medical School, MHICN inquires about whether it is possible for humans have excessive intake of SPMs. Dr. Serhan responds no as SPM operate under  a feed forward mechanism. 11. Insights from the Metagenics Lifestyle Summit 2015: Charles Serhan, PhD

Specialized Pro-Resolving Mediators (SPMs) offer an exciting opportunity to treat and manage the inflammation often associated with chronic disease. Inflammation exists in other settings as well, such as pre- and post-operative settings where healing will be necessary. Metagenics Institute asks Dr. Charles Serhan of Harvard Medical School if there is any data regarding pre- and post-operative use of SPMs for improved healing outcomes. Dr. Serhan responds that there is, indeed, data supporting that indication of SPMs. SPMs will not interfere…

Specialized Pro-Resolving Mediators (SPMs) offer an exciting opportunity to treat and manage the inflammation often associated with chronic disease. In this short video, we ask Dr. Charles Serhan of Harvard Medical School about the time of onset of action for SPMs following their ingestion. Dr. Serhan responds that, in a limited study of humans, the conversion of substrate is very fast. Within four hours, investigators could identify those patients who had taken pro-resolving mediators by testing the peripheral blood. Experiments…